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ABSTRACT

Two of the major effects of histamine in the rabbit heart are the
enhancement of contractility and microvascular permeability.
muscle it has been documented that calcium (Ca

In cardiac

) bound to the sarcolem-

mal-glycocalyx complex is essential for the regulation of the contractile
response.

In addition, it has been postulated that histamine's regula

tion of microvascular permeability may occur via an endothelial contrac
tile response causing the formation of submicroscopic gaps between endo
thelial cells.

It was postulated that these effects of histamine may in-

O.
volve an alteration of Ca r binding to the plasma membranes of these tis
sues.

In previous work I have shown that the calcium channel blocker

verapamil inhibits lanthanum (La^+) binding to the cellular surface in
the isolated rabbit heart, La^+ being used as an electron opaque marker
for Ca ’r binding sites.

For the present study I reasoned that if histaOi

mine increases cellular contractility by enhancing Ca

binding to the

Oi
plasma membrane, it may cause the reappearance of La r binding to the
cell membrane in the presence of verapamil.

I examined this by first

perfusing rabbit hearts with histamine (1.1 x 10“^ M) for 3 min, secondly
with histamine and verapamil (10-^ M) for 30 min, and subsequently with
histamine in the presence of La^+ (10 mM) and verapamil for 30 min.

Sub

sequent transmission electron microscopy revealed the presence of bound
La

on both the cellular surface and cytoplasmic vesicles of cardiac

myocytes and vascular endothelial cells which is in contrast to the absence of La T binding that occurs in the presence of verapamil alone.
This visual evidence of an apparent enhancement of La^+ binding under
histamine supports the hypothesis that histamine may exert its effects by

xi

2+
causing increased Ca 'r binding to the plasma membranes of cardiac and
vascular endothelial cells in rabbit myocardium.

Further work characterO.

O.

ized the type of histamine receptors affecting La r (Ca ‘r) by use of ap
propriate pharmacological agents.

Treatment of hearts with the H^-recep-

—7 M) prior to histamine reduced La 3+
"r

tor blocker diphenhydramine (3.4 x 10

binding to vascular endothelium but not myocardium.

Treatment of hearts

with the H^-receptor blocker cimetidine (4.0 x 10“^ M) prior to histamine
O.
reduced La

binding to both cell types.

xii

LITERATURE REVIEW

I.

Cardiac Muscle
A.

Morphology
1.

General Morphology

Striated muscle is contractile tissue that has been derived embryological ly from mesenchyme.
muscle exist:

In mammalian systems, two types of striated

skeletal and cardiac.

Muscle cells contain all of the

cellular organelles found in typical cells.

However, the cytoplasm is

termed sarcoplasm, and the plasma membrane is called the sarcolemma.

A

typical striated muscle cell is called a myocyte and the basic unit of
contraction is a sarcomere (1).

2.

Sarcolemma

The cardiac sarcolemma or plasma membrane is a complex, dynamic
structure consisting of two components:
structure called the glycocalyx.

a unit membrane, and an external

The unit membrane is a lipid bi-layer

matrix composed of phospholipid molecules with hydrophobic fatty acid
chains oriented inward and hydrophilic heads oriented outward (2,3).

An

important feature of the unit membrane is the presence of proteins and
glycoproteins interspersed within the lipid bi-layer (2,3).

These pro

tein structures are referred to as "integral" proteins (4).

These inte

gral proteins are thought to be involved in the formation of transmem
brane pores (4).
The second component of the sarcolemma is the glycocalyx (5).

The

glycocalyx is approximately 50 nm in thickness external to the unit mem
brane (2).

The glycocalyx itself is also sub-divided into two compon-

1

2

ents:

an inner coat, called the surface coat which is approximately 20

nra thick, and a denser, external constituent called the external lamina
which is approximately 30 nm thick (2).

In addition, the glycocalyx con

tains numerous oligosaccharide and carbohydrate chains derived from the
glycoproteins of the unit membrane (2,3) which give the sarcolemma a
"fuzzy" appearance (6).

It has been shown that these sugar moieties have

the ability to bind cations (5).
Observations have shown that calcium involved in excitation-contrac
tion coupling is bound to the glycocalyx before entry into the cell (7).
The integrity of the glycocalyx is important, if the glycocalyx is dam
aged, uncontrolled entry of Ca into the cell results (2).

Sialic acid, a

component of the glycocalyx, is essential for structural integrity and
maintenance of membrane selectivity for Ca (2).

3.

Sarcoplasmic Reticulum

In 1890 Retzius studied cellular organelles under the light micro
scope, and is therefore credited with the discovery of the sarcoplasmic
reticulum (SR) (8).

However, the actual term "sarcoplasmic reticulum" is

credited to Bennett and Porter (9) who observed the structure under high
resolution with the transmission electron microscope.
a network of tubules which surround the myofibrils.

The SR consists of

Enlarged ends of the

tubules (cisternae) are in close proximity to the sarcolemma via the Ttubules (10).

Similar to the sarcolemma, the SR consists of a bi-layer

matrix composed of phospholipids, triglycerides and cholesterol (10).
Proteins (MW 100,000), embedded in the lipid bi-layer and protruding
above the surface of the SR, have been found which exhibit and have a
very high affininty for calcium binding and contain a calcium stimulated

3

Mg-ATPase which is responsible for the active transport of calcium from
the sarcoplasm into the lumen of the SR (10).

In cardiac SR, a unique

protein associated with the core of the lipid bilayer is phospholamban
which when phosphorylated, greatly increases the transport rate of cal
cium across the SR membrane(ll).

4.

Mitochondria

Mitochondria are organelles responsible for oxidative phosphoryla
tion found beneath the sarcolemma surrounding myofibrils.

Those present

in cardiac muscle are more abundant than in skeletal muscle (12).

Evi

dence indicates that two types of mitochondria may exist, i.e., "subsarcolemmal" and "intermyofibrillar" types (13).

Associated with these

organelles are lipid droplets and glycogen granules which contribute to
the energy requirements of muscle.
Mitochondria are sites where Ca ions may be sequestered within the
muscle fiber (14).

Fabiato (15) has found that mitochondria are able to

sequester Ca ion when the myoplasmic free Ca T is greater than 4 x 10
M.

Other investigators have attempted to define the role of mitochondria
»
in the excitation-contraction coupling process (16,17), but no convincing

evidence exists for the active participation of mitochondria in excita
tion-contraction.

However, it has been stated that the affinity of
O.

mitochondria for Ca

, the total binding and storage capacity, and

velocity of calcium uptake processes are "theoretically adequate to
account for relaxation in cardiac muscle" (16).

4

5.

Contractile Proteins
a.

Myosin

Myosin is a large elongated molecule with a globular end for biolog
ical activity and a filamentous end which maintains the structural rigid
ity of the molecule.

Myosin is the major protein of the thick filament

in cardiac muscle (18).

Its length is approximately 160 nm and the mol

ecular weight is approximately 480,000 daltons.

The molecule can be

split into two fragments, "light" meromyosin and "heavy" meromyosin.
Light meromyosin consists of two a-helical polypeptide chains wrapped
around each other, and exhibits solubility properties characteristic of
myosin; heavy meromyosin contains the "head" of the molecule thought to
be the cross-bridge for contractile binding to actin (19).

Myosin, in

cardiac muscle, is seen as the anisotropic (dark) or A-band, as observed
under polarized light (20).

Other functions include ATP hydrolysis for

chemical energy in excitation-contraction coupling (21).

b.

Actin

Actin was first isolated in A. Szent-Gyorgyi's laboratory (22).
This protein was termed actin due to its ability to activate myosin
ATPase activity (18).

It is smaller than myosin, having a molecular

weight of approximately 42,000 daltons, and a diameter of approximately
5.5 nm (18).

There are two forms of actin; the monomeric form is refer

red to as G actin (G = globular), and the polymeric form is termed F-actin
(F = fibrous) (18).

In the sarcomere, actin exists in the polymeric form

which provides the "backbone" of the thin filament (18); this rigid
structure is composed of two strands of G-actin monomers wound around
each other forming a double helix.

The actin molecule is seen as the

5

thin filament or isotropic (I) band (light) seen under polarized light
( 1 ).

c.

Tropomyosin

Tropomyosin, a coiled protein discovered in 1948 by Bailey (18),
seemed to have no biological activity until it was found that it acts as
a modulator of interactions between actin and myosin.

The molecular

weight of the molecule is approximately 68,000 daltons (18).

The struc

ture consists of two peptide chains linked by a single disulfide bridge.
In the sarcomere, tropomyosin is bound stoichioraetrically to F-actin be
tween both F-actin polymer strands (18).

d.

Troponin

Troponin was first observed in 1965 by Ebashi and was thought in
itially to be a globular protein of approximately 50,000 daltons (18).
However, recent investigation has revealed that troponin is a complex
composed of three proteins:

troponin I regulates the interaction between

actin and myosin by inhibiting binding of actin to myosin (18); troponin
T binds the troponin complex to tropomyosin; troponin C contains two
high and two low-affinity binding sites for Ca

.

Troponin C exhibits

"positive cooperativity", that is, a strong interaction between the two
affinity binding sites such that when one site is bound by Ca
finity of the second site for Ca

2+

binding is enhanced.

effect is to amplify the Ca effect inside the cell (18).

the af-

The resulting
The troponin

complex is distributed along the actin filament at approximately 40 nm
intervals (18).

6

6.

Sarcomere

In the sarcomere, the I bands are bisected by demarcations called Zlines which are approximately 205 ym in width and are composed of a
lattice-like protein which interwines with the thin filaments (23).
Two successive Z-lines delineate the sarcomere, which in cardiac muscle
is approximately 2 to 3 ym in length (3).

A somewhat lower density region

referred to as the H zone is located in the center of the A-band (3).
The M-line, a narrow dark line bisecting the H zone (3) is composed of
an 88,000 dalton monomeric form of creatine kinase and a 165,000 molecular
weight protein (23).

B.

Physiology
1.

Role of Calcium

". . . it is evident that the normal (tension) trace is the result
of the antagonizing action of calcium and potassium salts" (S. Ringer,
1883) (24).
Ca ion, which has a valence number of +2 is a member of the group II
A metals, collectively referred to as the alkaline earth metals (25).
»
Its atomic radius is .174 nm and is represented by atomic number 20 on
the periodic table (25).

Ca^+ is involved in many essential physiologi-

cal functions, including excitation-contraction.

The role of Ca T in the

initiation and development of contraction in muscle has been known since
the time of Ringer (24), who observed an absolute dependence of myocardial
contraction on extracellular sources of Ca

24-

.

Currently, in agreement with Ringer, it is believed that extracel
lular Ca^+ is essential for excitation-contraction in cardiac muscle (2).
Specifically, the source of this extracellular Ca

2+

is binding sites on

7

the sarcolemmal-glycocalyx complex (26), sites which appear to be in
equilibrium with free cytoplasmic extracellular Ca^+ (27).
observed that two types of Ca

It has been

binding sites are present on the sarco

lemmal-glycocalyx complex, those with high affinity (Km ~ 20 mM) and those
with low affinity (Km ~ 1.2 mM) (26).

Evidence seems to indicate that the

low affinity sites are important in the regulation of myocardial contrac
tility (26).
The biochemical nature of the Ca

2-4-

binding sites has also been in-

o,

vestigated (27).

It is thought that Caz_r binds to negatively charged

residues on the sarcolemmal-glycocalyx complex such as sialic acid (28)
because removal of sialic acid residues reduce Ca "r binding and depress
myocardial contractility (3,29).

In addition to sialic acid, sarcolemmal

phospholipid may also be essential for Ca T binding, specifically, phosphatidylserine and phosphatidylinositol (30,31).
Two models are currently being investigated in the attempt to elucidate the mechanism of extracellular Ca
contractility (32).

regulation of cardiac muscle

The first model proposes that Ca^+ is released dir

ectly from the sarcolemmal-glycocalyx complex, enters the membrane through
(
specific pores or channels, and directly activates the myofilaments (32).
A second model suggests that a small amount of "activator" Ca^+ is re
leased from the sarcolemmal-glycocalyx complex, enters through specific
pores or channels and triggers the release of large amounts of Ca^+ from
intracellular stores such as the sarcoplasmic reticulum to initiate con
traction (15,33,26).

In addition,

speculation exists for the possible

release of Ca "r from mitochondria, thereby serving as a possible second
intracellular Ca^+ store (15).

8

2.

The Calcium Channel

The sarcolemma is a lipid bi-layer that is selectively permeable to
ions and is composed of phospholipid molecules which separate aqueous
compartments.

Macromolecular proteins, which traverse the lipid bi-layer

selectively allow specific ions to enter and leave the membrane; these
proteins are often referred to as "channels" (34).

Each protein or chan

nel is ion specific, that is, it allows primarily one species of ion to
enter and leave through its channel.

Ion channels consist of "gates"

that open or close depending on the charged regions of the channel pro
teins (35).
The calcium channel is specific for Ca^+ and is essential in cou
pling membrane excitation to physiological responses such as secretion
or contraction (36).

For example, Ca^+ channels have been observed to be

involved in activation of nodal regions of the heart (37,38), cilia of
Paramecium (39,40), and dendrites and growth cones of various neurons
(41,42).

However, the most recognized function of the Ca

the allowance of the passage of Ca

2+

channel is

2+ through the sarcolemma for the in

itiation of excitation-contraction (43-45).
In cardiac muscle, the time-dependent transitions of the sarcolemmal
Ca

2+ channels are much slower than the rapid sodium channels for passage

of their respective ions through the sarcolemmal membrane; for this
9 -4-

reason, CaZi" channels are usually referred to as "slow" channels (46).
Recent work has been done to quantify the number of Ca
in cardiac muscle.

channels present

For example, in the rat cardiac cell, it has been

n.
calculated that there are 2,000 to 10,000 functional Ca T channels with
each channel allowing the passage of approximately 300,000 ions through
the membrane each second (43).

9

Carbonyl groups associated with the channel may function as an ion
o«
selective filter by binding the specific (Ca "'') ion (43).
such that other structurally similar ions such as Ni
O i

Specificity is

, Mn

, Co

and

O i

LaJi_ are also able to bind to these Ca r binding sites (43).
O.
In general, it has been postulated that Ca

channels are activated

when they are phosphorylated via a cAMP-dependent protein kinase (46).
When the channels are phosphorylated, this allows the passage of Ca
through the membrane to initiate muscle contraction (46).

2+

For example,

in the SR membrane, phosphorylation of phospholamban causes increased
Ca^+ fluxes across the membrane via an ATPase calcium pump protein which
serves as a Ca^+ transport system (47).
It is thought that two types of sarcolemmal calcium channels are
present to allow calcium entry upon a signalled response (48):

potential

dependent channels (PDC) activated by membrane depolarization and recep
tor operated channels (ROC) activated via receptor binding independently
of membrane depolarization (49).

In addition, it has been suggested that

binding of agonists to their corresponding receptors opens ROC's, inOi
i
creases membrane permeability to Ca'^’1’ and possibly some Na , which can
21

then activate the PDC's via membrane depolarization allowing further Ca
passage through the cell membrane (50).
There are several different techniques employed to study slow chan
nels.

Usually the "fast" or Na+ channels are inactivated by voltage

clamping, K+ depolarization or tetrodotoxin (TTX) (51).

The slow chan

nels can then be activated by addition of substances that increase levels
of cyclic adenosine 5-monophosphate (AMP) such as isoproterenol, hista
mine and the methylxanthines (52).

A slow calcium dependent action po-

tential will be generated which will in turn trigger a Ca

-dependent

10

mechanical response (53).
There is relatively little information concerning the existence of
slow, Ca

O.
-selective channels.

The information available reveals that

they require ATP for maintenance (54), admit other divalent cations
through such as Ba^+ and Sr^+ (55), operate over a voltage range of -45
mv to -25 mv, and admit Na+ through a tetrodotoxin-insensitive pathway
(56) .
It is possible that the slow channel (Fig. 1) is controlled
by two gating mechanisms located in series along the channel membrane
(57) .

Outer and inner gates control the activation and de-activation of

the currents.

With depolarization, both gates are open, first allowing

Na+ then Ca^+ ions to pass through the slow channels.

Closing of the

inner gates results in de-activation of the channels, while opening of
the inner gates with the outer gates closed allows for restoration to the
resting potential.

3.

Excitation-Contraction Coupling

The sliding filament theory of excitation-contraction coupling was
introduced in 1954 (58).

However, mechanical data on excitation-contrac

tion had been obtained years earlier.

For example, early experimenters

based the concept of contraction on the behavior of a stretched spring
(23).

Fenn observed (59) that the total energy released in the form of

heat and mechanical work in frog sartorius muscle was greater in twitches
of isotonic tension, rather than isometric tension.

A.V. Hill (60)

proposed a new type of model, whereby a muscle would develop more heat in
isotonic contractions, and the extra heat produced was solely dependent
on the amount of shortening.
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It was not until 1954 that a structural basis for contraction was
postulated (58).

This postulate, termed the sliding filament model, is

still the basis for theories on contraction thirty-two years later.
Huxley and Hanson observed that the I bands and H bands lengthen with
stretching and shorten upon contraction of the myofibril.

With maximal

contraction the A bands meet at the Z line, with the I band not visible.
From this they suggested that the sliding filaments are the actin and
myosin proteins which interdigitate with each other upon contraction, as
the cross-bridges of the myosin molecule latch onto the corresponding
positions on the actin molecule.

It appears that the proteins slide

across each other; actually actin filaments attached at the Z-line, slide
across the myosin filaments and fold when the myosin filaments meet the
Z-line.

The reverse occurs as the muscle relaxes.

has been updated.

Since 1954 the theory

For example, Podolsky (61) verified Huxley's hypothe

sis by postulating that the thin filaments attach to the thick fila
ments .
At the present time the understanding of the excitation-contrac
tion coupling process can be stated as follows.

The initiation of an

action potential depolarizes the sarcolemma and the T-tubule system.
Oi
Ca

influx occurs through specific pores or channels which is dependent
O i

O i

on the extracellular Ca r concentration; this Ca
the plateau phase of the action potential (62-64).
O .

cellular Ca

influx occurs during
In addition to extra-

O i

influx, superficially bound Ca

at the sarcolemma is

mobilized and participates in the Ca "r flux associated with contraction
(7,65,66).

The influx of Ca^+ and the release of superficially bound

Ca^"'" mediates the release of intracellular stores of bound Ca
sarcoplasmic reticulum (15), and mitochondria (16,17).

from the

The Ca^" mobi
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lized from all of these sources raises the concentration of ionized Ca
—7
above 10
M in the area of the myofilaments.
nin, which inhibits the tropomyosin complex.

2+

7+
Ca T then binds to tropo
As a result, initiation of

actin-myosin complex formation develops which leads to the contraction of
the myofibrils.

4.

Relaxation

An extract of muscle, discovered in 1952 by Marsh (67), was found to
elicit relaxation in glycerinated muscle fibers (68,69).

Analysis of

this extract revealed a tubular matrix (70-72) which was identified with
the SR and therefore lead to the conclusion that the SR is partly responsible for relaxation.

It is now accepted that a Ca "r stimulated Mg ‘r

dependent ATPase pumps Ca^+ through the SR membrane thus reducing free
Ca^+ concentration around the myofilaments (73).

This is an energy

dependent transport system (74).
O.
It appears that in addition to SR Ca T uptake, other physiological
mechanisms lower Ca^+ concentration around the myofilaments (28).
example, it is postulated that mitochondria may serve as a Ca
the myocardial cell, thereby lowering free myoplasmic Ca
in the relaxation process (73).

2+

2+

For

sink in

concentration

In addition, there are two possible

mechanisms of Ca^+ removal through the sarcolemma which may contribute to
cardiac muscle relaxation (28).

One of these mechanisms involves extru

sion of Ca^+ via Na+-Ca^+ exchange, whereby Ca^+ is removed from the
cell and Na+ is taken up passively (75,76); the second mechanism involves
extrusion of Ca^+ via a Ca ATPase enzyme energy dependent transport sys
tem, as seen in SR (28).
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II.

Vascular Endothelium
A.

Morphology

Endothelial cells are squamous shaped cells that form a portion of
the tunica intima or innermost layer within blood vessels and are approx
imately 0.1-0.5 pirn in diameter (1).

Transmission electron microscopy has

revealed that the endothelial plasma membrane appears to consist of
primarily glycosaminoglycans, (77,78) which are secreted by the endothel
ial cell (79), oligosaccharide moieties of glycoproteins and glycolipids
(80),

and sialo conjugates (81).
There are numerous organelles present in an endothelial cell which

include mitochondria, Golgi apparatus, centrioles and free ribosomes
(82).

Fine filamentous structures are also present which presumably form

a cytoskeletal framework (82).

These filaments include actin and inter

mediate filaments (82), the latter containing vimentin, a filamentous
protein found in cells of mesodermal origin (83).
A characteristic feature of endothelial cells is the presence of
numerous cytoplasmic vesicles, currently given the term plasmalemmal
vesicles (84), ranging from 60 to 100 nm in diameter (1). There are
O
approximately 875 vesicles/mnr of cytoplasm; 30% are open at the luminal
(adluminal) surface of the endothelial cell, 40% are open at the inter
stitial (abluminal) surface, and the remainder appear to be free in the
cytoplasm (85).

B.

Ultrastructural Role in Microvascular Permeability

The concept of microvascular permeability dates back to the end of
the 19th century when E.H. Starling studied the phenomenon of fluid ab
sorption from connective tissue spaces (86).

Microvascular exchange
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appears to involve both capillaries and post-capillary venules (84).
Specifically, the

endothelial cell layer is the primary barrier to

transcapillary or transvenule solute and fluid exchange.

The capillary

endothelial cells present in cardiac muscle are of the low, continuous
type; ie., they are characterized by a complete layer of cytoplasm
throughout each endothelial cell which are joined by junctional com
plexes (1).
The concept of permeability is extremely complex.

There are theo

retically two types of molecules (lipid soluble and water soluble) that
are able to traverse the endothelial cell membrane.

Evidence exists for

the passage of high and low density lipoproteins through the cell mem
brane (87).

Particles the size of chylomicrons are presumably hydrolyzed

at the endothelial cell surface into products that are both lipid soluble
and of suitable size for transmembrane passage (88); these lipid soluble
particles then dissolve into the cell membrane and via diffusion or ves
icular transport reach other membrane contact points (88).
The "Pore Theory" is used in the description for the passage of
water and water-soluble molecules.

Evidently, the rapid transmembrane

passage of water and water-soluble molecules implies the existence of
some hydrophilic pathway connecting the vascular lumen with the intersti
tial space (84).

According to current literature on the Pore Theory, the

raicrovascular endothelium may contain two sets of pores of relatively
stable size, geometry, and density (84).

Small pores have a diameter of

approximately 1-2 nra, a frequency of 15-20 units/ymz and an aggregate
area of 0.1%; large pores have a diameter of 5-70 nm, but the frequency
decreases to 1/20 ym^ (84).

In the past two decades, ultrastructural

studies and tracer experiments have been done to identify the endothelial
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cell structures that could represent morphological "pore" systems.

How

ever, the morphological characteristics of the endothelial cell membrane
are structurally and biochemically highly differentiated.

Therefore,

molecular transport is considered to be a more active, dynamic, refined
process which is not adequately explained by the pore theory (89).

Cur

rently, there are two ultrastructural mechanisms postulated in the regu
lation of microvascular permeability; the formation of transendothelial
channels by vesicular fusion and alteration of intercellular clefts by
endothelial cell contractility.
Membranous vesicles ranging up to 60-80 nm in diameter are present
on and within the endothelial cell membrane.

The membranes of the sur

face-bound vesicles are continuous with the plasraalemma; therefore, the
term plasmalemmal vesicles is more commonly used (90).

It has been pro

posed that plasmalemmal vesicles can form fused chains which can simul
taneously open on both sides of the endothelial cell to form a transendo
thelial channel (91).
documented (92-94).

The appearance of transendothelial channels is

It has been hypothesized that these channels are

a major pathway for the permeability of macromolecules (95-97).

These

channels also appear more frequently in venular segments of capillaries
(98), but their actual numerical density has not been established.
I
Transendothelial channels are presumed to behave similar to dynamic
hydrophilic pathways (89) that function as either small pores (91) or
large pores (96).
Currently, the research done on plasmalemmal vesicles shows that 1)
plasmalemmal vesicles appear to be a relatively stable population of the
cellular components; 2) endothelial cells, and therefore by deduction
plasmalemmal vesicles, have an ability to take up and discharge macromol
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ecules; 3) vesicular uptake discriminates in favor of anionic proteins;
4) this uptake process is influenced by temperature and the molecular
composition of the surrounding medium (78).
apparently receptor mediated (99).

These processes are also

Researchers now use the terra "trans-

cytosis” to describe the transfer of substances via transendothelial
channel exchange (84).
A second mechanism of regulation of microvascular permeability in
volves the relatively new concept of endothelial cell contractility.

It

has been observed that contractile proteins, which form a microtrabecular
lattice, are present in vascular endothelium.

Thin actin filaments (ap

proximately 6 nm) have been detected in brain capillaries and postcapil
lary venules (100).

Thick filaments (15 nm) have been identified as

myosin in capillaries and postcapillary venules (101).

Therefore, it is

conceivable from an ultrastructural point of view that endothelial cell
contraction is a distinct possibility in the regulation of microvascular
permeability.

For example, it has been postulated that endothelial cell

contraction may widen intercellular clefts between endothelial cells of
capillaries and postcapillary venules which would enhance microvascular
permeability (102).
Tracer studies have shown that intercellular endothelial clefts of
continuous capillaries represent a major pathway for the transport of
small peptides up to molecular weight 1,900, and to a limited extent, the
passage of proteins as large as 40,000 daltons (103-106).

These findings

are in general agreement with earlier studies which indicated that mole
cules with molecular weights of less than 10,000 (3 nm) are able to
traverse through endothelial clefts with little restriction and that
molecules in the molecular weight range of 10,000 to 40,000 (3 to 5 nm)

17

are severely restricted when crossing the endothelium via intercellular
clefts (107).
Therefore, it would appear that microvascular permeability depends
on the type of molecule being transported and the method of transport
being employed.

Molecules up to 5 nm in diameter appear to be able to

cross via intercellular endothelial clefts while larger molecules may be
transported via transendothelial channels.

III. Lanthanum
Lanthanum (La^+), a member of the lanthanide series of rare earth
metals, has an atomic radius of .169 nm, an oxidation state of 3+ and
atomic number 57 on the periodic table (25).

La^+ binds by electrostatic

interactions exhibiting a preference for oxygen ligands over nitrogen li
gands when forming complexes and has an affinity for negatively charged
glycoproteins on the surface coat of the plasma membrane due to its cat
ionic nature (108).

The ion may also bind with great affinity to the in

ner surface of the membrane by complexing with phosphatidylserine and
phosphatidylethanolamine. These phospholipids are more predominant on
»
the inner membrane surface (109).
O.
It was first observed in 1910 that La
contractility in the frog heart (110).

had inhibitory effects on

It 1964, it was postulated that

LaJ , having an ionic radius similar to Ca

and a higher valence number

than Ca^+, would bind readily to superficial Ca^+ binding sites (111).
Doggenweiler and Frenk (109) introduced La^+ as a stain for biomem
branes in 1965, possible because it is opaque under electron microscopy
(112) .

La^+ binds to Ca^+ binding sites on the lobster axon membrane

(113) and inhibits Ca^+ uptake and transport in the squirrel axon (114),
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rat liver mitochondria (115), mammalian smooth muscle (116) and cardiac
muscle (117).
In all three types of muscle (smooth, cardiac, and skeletal) La^+
9-4-

has been shown to prevent Ca ^ binding to plasma membranes (117,118,119).
In frog sartorius muscle, La

binds at superficial sites to displace Ca

and prevent contractile responses and ionic movements (118).
La^+ has been used to demonstrate the permeability properties of
endothelium in blood vessels (120) and has been observed to inhibit Ca

2+

binding in guinea pig longitudinal smooth muscle of the ileum (121),
taenia coli (122), rat uterine smooth muscle (123) and rabbit aortic
smooth muscle (124).
Most information known about the effect of lanthanum in muscle pertains to cardiac tissue.

It appears that La0-1" inhibits Ca "r uptake and

release at superficial binding sites (125).

Through transmission elec-

O1
tron microscopy it has been found that LaJ-r binds to the external lamina
and glycocalyx, a cell layer approximately 0.06 to 0.1 u in thickness
(117).

In chick embryonic hearts, the Ca

channels present in early deO 1

O,

velopment are blocked by LaJ+ (126).

In cultured rat heart cells, La

prevents Ca ^ efflux and uptake and also displaces Ca

at superficial

binding sites (117,118).
O,
In the perfused rat heart La

has an affinity for muscle and non

muscle cells as well as the luminal surface of capillary endothelium
(127).

It was observed that when the rat heart was perfused with LaClg,

permeation through capillary walls occurred through endothelial clefts
(intercellular clefts) and plasmalemmal vesicles of endothelial cells
Ot
(127).

Weihe also verified Langer's observations that La

stained the

basal lamina and plasma membrane of cardiac myocytes, also noting that
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both the cytoplasmic vesicles and T-tubule system of the myocytes were
OI
Q.
stained by La T and, intracellularly, that La T binds to the sarcoplasmic
reticulum, I, A and Z bands of the sarcomere (127).

However, in rabbit

cardiac muscle, it bound relatively poorly to the sarcoplasmic reticulum
and the sarcomeres (128).
The concentration of extracellular lanthanum appears to be a factor
in its affinity for binding to Ca^+ sites (118).

When 10 mM lanthanum is

used, this concentration is apparently sufficient to block all “^ C a up
take and binding (129).

IV. Calcium Channel Blockers
A.

General Properties

The concept of "calcium antagonism" or "calcium channel blocking" is
relatively recent.

The pioneer in the field is A. Fleckenstein, director

of the Physiological Institute,
of Germany.
ered.

University of Freiburg, Federal Republic

It was by chance in 1963 that calcium antagonism was discov

Two coronary vasodilators were synthesized (130) by Knoll and

Hoechst pharmaceutical companies which had unexplained cardiac depressant
side effects; these compounds were prenylamine and Iproveratril, later
to be called by its generic name verapamil (131).

Analysis of these sub

stances' actions revealed inhibition of excitation-contraction coupling
with an associated effect on the action potential (132).

These compounds

O.
also lowered oxygen utilization and high energy Ca
consumption.

dependent phosphate

All of these inhibitory effects could be reversed by the

addition of cardiac glycosides, (3-adrenergic catecholamines, or increased
extracellular Ca^+.

Subsequently, it was postulated that the mechanism

o»
of action might be the interference with Ca r which is essential for
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excitation-contraction coupling in cardiac muscle (133).
t

In 1969, methods became available to measure Na
separately.

Oj

and Ca

currents

Using voltage clamping techniques (134) it was seen that these

new compounds could selectively inhibit the trans-sarcolemmal Ca
rent.

cur

After these initial findings, it was also found in 1969 that vas

cular tone and vasoconstriction could be suppressed by small doses of the
calcium antagonists in intestinal and vascular smooth muscle cells (135);
Oj

it was thought once again that the transmembrane Ca

current was inhib

ited, which led to the excitation-contraction uncoupling of the smooth
muscle cells.
The original term "calcium antagonist" is sometimes interchanged
with "calcium channel blocker".

This is due to the fact that the primary

entry route for Ca^+ affected by these drugs is through the slow channels
(136).

It is now known that calcium antagonists exert their pharmacologi

cal effect through the cell membrane of excitable tissues (137); they do
not modify Ca^+ uptake, binding or exchange by cardiac microsomes, nor do
they have an effect on calcium activated ATPase (137).

Their mechanism

of action is distinct from 3-adrenoceptor blocking agents, as their main
locus for activation is inhibiting the superfically-located membrane
O.

storage sites for Ca^"r (137).
Currently, organic calcium channel blockers have been classified
into three groups (138).

Group I includes the dihydropyridines of which

nifedipine is the parent compound; Group II includes the phenylakylamines
which include verapamil, gallopamil (D-600, a methoxy derivative of ver
apamil), and diltiazem; Group III includes the diphenylalkylamines which
include cinnarizine, flunarizine and other derivatives (138).
It has been postulated that each class of compound has a specific
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cellular site of action (138).

For example, evidence exists for a spec-

O
ific receptor for 1,4 dihydropyridines (139), as [JH] nitrendipine and
O
other [ H] 1,4 dihydropyridines exhibit specific binding to excitable
tissues (140,141); this receptor appears identical or closely related to
sites at which Ca^+ channel antagonism occurs (142) as electrophysiologically, dihydropyridines inhibit passage of current through Ca

channels

(143,144).
The phenylalkylamines and diphenylalkylamines also appear to have
specific membrane binding sites (138) although the molecular composition
of these sites has not been fully elucidated.
It has also been determined that each class of calcium channel
blocker exerts specific pharmacological effects (145).

For example, the

dihydropyridines are potent peripheral vasodilators (145), the phenylal
kylamines exert their effects primarily in cardiac muscle and the dipheny
lalkylamines exhibit pharmacological effects in both cardiac and smooth
muscle, with preference being given to smooth muscle (145).

However, it

should be noted that all three classes of compounds can exert physiologi
cal effects in either tissue if concentrations of the compounds are suf»
ficient (145).
Even though specificity of calcium channel blocker binding sites
appear to be present, the actual mechanism of channel blockade may be
similar (45).

For example, it appears that a particular compound may

actually plug the "mouth" of the channel when these channels are in the
open or activated state (46).

Another possible mechanism of blockade may

involve interaction of calcium channel blockers with hydrophilic regions
of the membrane where they could modify channel function via structural
changes in membrane structure (146).

A third potential mechanism of ac
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tion is allosteric intervention of Ca

91

passage through the channel it

self (46).

B.

Verapamil

As stated previously, Iproveratril (verapamil) was synthesized by
Knoll and Hoechst pharmaceutical companies and characterized by A. Fleckenstein in 1963.

The structural formula of verapamil is shown in Figure

2.
In 1968, a methoxy derivative of verapamil was synthesized which was
much stronger than its predecessor; this compound was labeled "D-600",
now called gallopamil (138; Figure 3).

Gallopamil is postulated to be

five times stronger than verapamil when inhibiting the trans-sarcolemmal
Ca^+ current and blocking tension development (147).

It has been calcu-

lated that one molecule of verapamil neutralizes approximately 4,000 Ca

2+

ions (148).
The structure-activity relationship of verapamil reveals that the
tertiary amino nitrogen and aromatic rings are essential for the negative
inotropic action of the compound (149).

The enantiomers of verapamil have

specific structure-activity relationships of their own; it has been shown
that the (-) enantiomer is responsible for the Ca

channel blocking ac

tivity of the drug, while the (+) enantiomer inhibits the fast sodium
current of the sarcolemma (150).

The optical isomers of gallopamil pro

duce the same stereo specific effect, except they are up to eight times
stronger (150).
The pharmacokinetics of verapamil have been studied using mass spectrometric and radioactive chromatographic techniques (151).

After admin

istration, plasma levels peak within 30 to 45 minutes and absorption is
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approximately 90% effective (57).

Intact verapamil is 88 to 92% protein-

bound to both albumin and a-1 acid glycoprotein (152).

Metabolism of

verapamil occurs via cleavage of the C-N-C bond by N-alkylation at the Catom in the shorter side chain (57), the cleavage product being only 5 to
10 percent active pharmacologically.

As more cleavage products are formed,

their plasma level eventually exceeds that of intact verapamil (153).
Verapamil is eliminated exclusively by the liver (154).
Verapamil exerts its strongest effect on cardiac and smooth muscle.
Verapamil has been shown to cause marked vasodilation in most peripheral
vascular beds including mesenteric and canine hind limb preparations
(137).

A competitive antagonism was observed between verapamil and Ca

2+

in depolarized vascular smooth muscle of rabbit main pulmonary artery
(155).

It has been proposed that verapamil relaxes smooth muscle by bind

ing to the sarcolemmal slow channels as well as reducing the activation
of calcium dependent myofibrillar ATPase (156).
Verapamil shows a negative inotropic effect on cardiac muscle (137).
In addition, Ca

uptake is inhibited in cardiac muscle cells when stim

ulated by isoproterenol (148).

Verapamil has also been shown to inhibit

the slow current in feline ventricular myocardium (157) and bovine Purkinje
fibers (56).

The effect of verapamil is not confined to smooth and car

diac muscle, as it has been found that verapamil interferes with pituitary
Ca^+ uptake which results in a depression of ACTH, GH, and TSH (158).
Verapamil inhibits noradrenaline release by inhibiting transmembrane Ca
influx into terminal sympathetic fibers (159); contractions produced by
serotonin, histamine and pitressin are also inhibited (160).
It has been postulated that in addition to blocking at the PDC's,
verapamil might bind to the ROC's.

An interaction is possible between

2+
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the blocker binding site and the cation channel site, whereby binding to
an allosteric site changes the conformation of the cation channel site
such that the cation channel becomes "plugged" (49).

Verapamil is a

neutral molecule which is not likely to react with a charged site (161).
It can bind to the lipoproteins of the inner surface of the plasmalerama
(162), which are possible allosteric binding sites.

When sarcolemmal

preparations are exposed to neuraminidase, the binding capacity of verap
amil is increased; since neuraminidase removes sialic acid residues, it
is unlikely that verapamil binds to the sialic residues of the basement
membrane coat (163).

Pretreatment with phospholipase C, acetylglucosam-

inidase and trypsin decreases the binding capacity of verapamil (163).
It is possible that verapamil causes an allosteric interaction by binding
to both glycolipids and glycoproteins of the plasmalemraa (147).
Contradicting evidence exists for the supposition that calcium
channel blockers are able to bind intracellularly; however, the lipophil
ic nature of the methoxy (OCHg) groups would seem to allow penetration of
the membrane (150).
It has recently been observed that verapamil can enter and accumulate
inside cardiac and smooth muscle cells (164); due to its lipid solubility,
it may enter the membrane via interaction with the lipid bilayer matrix
(164).

Evidence also exists for the passage of gallopamil through the

cell membrane to reach its specific receptor (165).

As a result, their

Ca^'r antagonistic properties could be expressed via activation of a Ca

-

dependent ATPase enzyme or blockade of Ca^+ at the sarcoplasmic reticulum,
mitochondria, myofibrils and internal portion of the cell membrane (147).
However, it has been shown in SR that any attempt to show an inhibo.
itory effect on Ca ^ accumulation, binding or uptake upon administration
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of verapamil has failed (160).

Other experiments have shown that verapa

mil has no effect on skinned cardiac muscle fibers (156) or skinned smooth
muscle fibers (160); therefore, it would appear that the major site of
action of verapamil is the plasma membrane.

It is

possible that calcium

channel blockers exert their effect through the transverse tubular system
(TTS) which is open to the extracellular space (150), but very little
evidence exists for such a hypothesis (166).

However, recent investiga

tions have revealed that calcium channel blockers might have a mechanism
of intracellular interaction with mitochondria (167) and with the regula
tory protein calmodulin (168).
The actions of calcium channel blockers can be reversed by the ad
dition of certain agents (160).

For example, the addition of calcium ions

to the extracellular fluid or stimulation of 8 -receptors counteract the
negative inotropic effect exhibited by the calcium antagonists (156).

In

addition, the cardiovascular system seems to have a regulatory mechanism
which opposes the calcium antagonistic effect.

That is, each time a drop

in blood pressure occurs, a release of sympathetic catecholamines is
elicited which partly abolishes the drug induced inhibition since calcium
antagonists do not interfere with beta sympathetic catecholamines directly
(169).
Clinically, calcium channel blockers have been widely investigated.
Europe has been using calcium antagonists therapeutically for over ten
years.

Verapamil has been used for the treatment of angiospastic (spon

taneous) angina with reversible S-T segment elevation and transient G
waves which can be seen on an electrocardiogram (57).

Verapamil is also

the drug of choice for the treatment of re-entrant supraventricular
tachycardia on the grounds that it lengthens the effective and functional
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refractory period of the A-V node and prolongs the A-V nodal transmission
time (170).

Verapamil improves conduction in ischemic areas (171) and has

been used as a treatment for arterial hypertension, but only small de
creases in arterial pressure have been seen (172).

However, there are

reports that verapamil still may be effective in treatment of systemic
and primary pulmonary hypertension (173).
It has been demonstrated that verapamil prevents the development or
alleviates heart lesions in the cardiomyopathic hamster (174); therefore
it might be beneficial to use calcium antagonists to prevent hypertrophic
obstructive cardiomyopathy in human beings (57).

Verapamil can be used

in place of beta blockers for treatment of chronic stable angina, espe
cially in patients with recurrent asthma, obstructive lung disease, sinus
or atrioventricular node disease, or having a central nervous system ad
verse effect to beta blockers (34).

Verapamil also reduces the size of

infarcts produced by ligation in laboratory animals (175).

Preliminary

findings suggest that verapamil may be beneficial in the control of ar
rhythmias associated with arterial disease, mitral-valve prolapse, or
digitalis toxicity (34).

Verapamil exerts its anti-arrhythmic actions

most effectively at the A-V node by prolonging the nodal refractiveness.
This is done via blocking of slow channels in the node proximal to the
bundle of His (34).

However, it does not appear to be the drug of choice

in the treatment for ventricular arrhythmias (137).
In the treatment for congestive heart failure, verapamil could
potentially reduce the afterload in patients with left ventricular fail
ure (34), by dilating coronary arteries and relaxing the myocardium.
There are numerous side effects associated with the administration
of verapamil (176).

For example, atrioventricular block and asystole have
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been observed in some patients given verapamil (177); other unwanted side
effects include dizziness,

V.

headaches, and constipation (176).

Histamine
A.

Early Work

B-aminoethylimidazole or histamine (Fig. 4) was first subjected to
intensive pharmacological study by Dale and Laidlaw in 1910; these early
investigators were the first to observe that histamine is synthesized when
carbon dioxide is split off from the amino acid histidine (178).

However,

it was not until 1936 that a histidine decarboxylating enzyme was discov
ered (179).

This enzyme is now called histidine decarboxylase (180), the

L form of which is responsible for the decarboxylation of histidine (181).
Histamine was first detected as a uterine stimulant in extracts of
ergot; it is also from these extracts that the first sample of histamine
was isolated (181).

However, these samples of histamine proved to be

contaminants of ergot resulting from bacterial action (181); therefore,
it was originally believed that histamine was produced as a result of
putrefaction (181).

It was not until 1927 that Best et al. (182) isolated

histamine from fresh samples of liver and lung, which established the
fact that histamine was a naturally occurring amine in mammalian systems.
As late as 1950, histamine was still not considered a physiological
substance (180).

At a symposium at the Royal Society of London, histamine

was considered a pathologically occurring amine, designated as "not
strictly physiological" and "... liberated when cells are injured" (183).
However, by 1960, histamine was accepted as a naturally occurring compound
physiologically, as it was found to be present in a great variety of nor
mal tissue (184), hence the name histamine after the Greek word for tissue,
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histos.
In most tissues histamine is primarily stored in mast cells or baso
phils and is synthesized and stored in secretory granules of these cells
(181).

Other storage sites include epidermis, chromaffin cells, neurons

in the CNS, and gastric mucosal cells (181).
In the 1950's the principal routes of histamine metabolism were
being elucidated (180).

It would now appear that the primary means of

metabolism include oxidative deamination via diamine oxidase and methylation (185).

B.

Histamine Receptors

In 1966, Ash and Schild (186) identified the first receptor associated
with the effects of histamine on guinea pig ileum and rat uterus.

They

observed that specific classical histamine antagonists could inhibit the
effect of histamine on rat uterus, but not on guinea pig ileum (186).
Thus, it was proposed that the specific histamine receptor causing inhib
ition be designated by the symbol

(186).

The work of Ash and Schild

also supported the concept that histamine may exert its effects via two
receptor types (186); this finding was in agreement with the suggestion
made by Folkow et al. in 1948 that the effects of histamine may be mediated
by more than one receptor (187).
In 1972, Black et al. (188) documented that a second type of histamine
receptor was present, but instead of designating these receptors as "nonH^", it was decided to provisionally identify them as H 2 (188).

Work

was started in 1964 to classify the histamine responses not blocked by
mepyramine, a specific

blocker, and eight years and seven hundred com

pounds later burimamide was synthesized, the first H 2 receptor antagonist
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known (188).
Currently, there are still only two histamine receptor subtypes re
ported in the literature, designated

C.

and H 2 (189).

Effects of Histamine on the Cardiovascular System
1.

General Effects

Histamine exerts a variety of physiological effects which are well
documented (180).

Specifically, the cardiovascular system represents a

major site for many of these effects (189), among them vasoconstriction,
vasodilation, inotropic, chronotropic, and dromotropic changes as well as
alterations in microvascular permeability (189-193).
The cardiac effects of histamine were first observed by Dale and
Laidlaw (178) who documented that histamine increased heart rate and con
tractility in the rabbit and cat (178).

They were also the first to ob

serve the effect of histamine on the systemic vasculature (178), and ob
served that the effect of histamine on arterial blood pressure is complex,
not easily interpreted and varies from species to species and in animals
of the same species (178).
Since the time of Dale and Laidlaw, numerous investigators have ex
amined the effect of histamine on the cardiovascular system including
Gunn,

1926; Staut and Grossman, 1930; Went and Lissak, 1935; Went et al.,

1952 and

Penna, 1959 (194-198).

2.

Role of H -^ Receptors in the Heart

The effect of histamine on the mammalian heart was first reported in
1910 (178).

Subsequently,

in the 1930?s, (199-200) research was conduct

ed to examine the effect of histamine on cardiac output.

In the same
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time period, work was also being done to examine the effect of histamine
on heart rate and contractility (194-196).

With the discovery of the

receptor in 1966, many investigations were carried out in the late 1960's
to examine the effect of H-^ receptor stimulation on the heart (189).

In

addition, earlier work on histamine (prior to the discovery of the H-^ re
ceptor) was being repeated to see if an

receptor mechanism was involved.

Currently, it appears that the cardiac effects of

receptor stimulation

are both species and tissue dependent (189).
There are a variety (but not all) of mammalian species which contain
cardiac Hj receptors (189) including the guinea pig, which is generally
considered the prototype species for histamine research (189).

It has

been documented that the guinea pig left atrium has an abundance of Hj
receptors (201,202).

These investigators report that stimulation of atrial

receptors cause an increase in the inotropic response (20 2 ), which are
blocked by diphenhydramine (Fig. 5) and mepyramine, potent H-^ antagonists
(2 0 1 ).

H-^ receptors are also present, though fewer in number, in the

right ventricle (202 ); their role in the inotropic response appears to be
minimal (202).

It has also been suggested that a negative droraotropic

effect in guinea pig heart is mediated via Hj receptor stimulation (203)
as it appears that

receptors located at the atrioventricular node mod

ify atrioventricular conduction (203).
The rabbit heart has been investigated for the presence of
tors (190,192,204-206).

recep

Evidence has indicated that the inotropic re

sponse in left atria, right ventricle, and papillary muscle is H-^ recep
tor mediated (205); H-^ receptor stimulation may also be involved in the
chronotropic response of the right atria (206).
In the canine heart, dromotropic, inotropic and chronotropic effects
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appear to be predominantly

receptor mediated (191).

These observations

support the earlier work of Flacke et al. (207) who observed that H^ an
tagonists such as diphenhydramine or promethazine reduced the inotropic
and chronotropic responses and completely abolished the dromotropic re
sponse in the isolated dog heart-lung preparation (207).
In human myocardium, there is very little evidence for involvement
of

receptor mediation in cardiac function.

However, Guo et al. (208)

have reported evidence for a decrease in myocardial contractility medi
ated via

receptors; to date, this is the only evidence for H-^ recep

tor involvement in human heart.

3.

Role of H 2 Receptors in the Heart

It is well documented that H 2 receptor stimulation affects the mam
malian heart (190,192,203,209) as evidence exists for the involvement of
H 2 receptor mediation on guinea pig, human and rabbit myocardium (190,
203,209).

Specifically, both inotropic and chronotropic responses in

these species are enhanced when H 2 receptor stimulation occurs (190,203,
209); these responses can be attenuated in the presence of H 2 antagonists
>
such as ciraetidine (Fig. 6 ) or burimamide (190,203,209).
It has also been postulated that only specific regions of the heart
possess H 2 receptors (202).

For example, evidence indicates that only

guinea pig right atria, papillary muscle and ventricles possess H 2 recep
tors (202).

In addition, conflicting evidence exists for H 2 receptor in

volvement in the inotropic response as some investigators have stated
that only the chronotropic response is H 2 receptor mediated (201).

Thus,

it appears that cardiac H 2 receptor mediation, like H^ receptor mediation
is both species and tissue dependent.

Also, it appears that the guinea

32

pig heart has the greatest tissue variability with regard to the presence
of Hj and H 2 receptors.
Evidence indicates that H 2 receptor stimulation may increase cir
culating levels of cyclic AMP (cAMP; 210,211).

Therefore, it is possible

that cAMP may potentiate histamine's H 2 cardiac effects as it has been
shown that cAMP is involved in phosphorylation of the calcium channel, which
causes activation, thus allowing passage of calcium to occur (28).

Addi

tional evidence has also shown that H 2 receptor stimulation in human myo
cardium can increase levels of adenylate cyclase, an enzyme essential to
the formation of cAMP (210).

4.

Role of Calcium in the Cardiac Effects of Histamine
O 1

Evidence exists for the involvement of Ca T in the cardiac effects
of histamine (212-215).

Specifically,

it has been reported that histamine

stimulates Ca T fluxes (216,217) by increasing Caz'1' conductance of the
surface of the cell membrane (212).
tion may cause Ca

It appears that

receptor stimula-

flux directly, while H 2 receptor stimulation activates

adenylate cyclase to increase levels of cAMP which may then alter (enhance) Ca^r flux across the membrane (215).

Josephson et al. (213) have

documented that histamine has a direct effect on chick ventricular myocardial cells to increase the number of available Ca ’r channels; H 2 re
ceptor stimulation may mediate this response (214).

5.

Effects on Microvascular Permeability

Histamine's affect on microvascular permeability is well documented
(193,218,219,220,221).

One of the postulated mechanisms by which hista

mine enhances permeability is by increasing the number of large pores in
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microvascular endothelium (222 ); it appears that histamine has no effect
on the small pore system (223,224).
Transmission electron microscopic evidence has shown that large pores
can occur through the formation of intercellular gaps between endothelial
cells (225).

It is now believed that these large pores can vary from 2

to 500 nm in diameter (220,226).

Majno et al. (227) originally thought

that histamine induced the formation of endothelial gaps via endothelial
cell contraction.

This belief was based on ultrastructural findings such

as nuclear cell pinching, accumulation of cytoplasm in the center of cells,
and the folding of subnuclear cytoplasm (225).

Additional evidence sup

ports the theory of endothelial cell contraction as a mechanism in the
regulation of microvascular permeability.

For example, immunofluorescent

techniques have shown that the contractile proteins actin and myosin are
present in endothelium (101).

In addition, evidence exists for the pres

ence of tropomyosin in vascular endothelium (228).

Also, Drenckhahn

(229) has reviewed studies that postulate the presence of actin and myo
sin filaments closely associated with endothelial cell junctions; these
filaments may influence endothelial gap size (230).
It appears that the post-capillary venules represent the major site
for the regulation of microvascular permeability (84); this concept sup
ports the earlier findings of Majno et al. (225) that endothelial cell
contraction occurs primarily in the postcapillary venules.

In addition,

the localization of histamine receptors on vascular endothelium has been
detected with a biologically active histamine-ferritin conjugate (84).
It appears that these histamine binding sites are more dense on post
capillary venules than on capillaries (231).

These binding sites are

also in close proximity to the contractile elements of vascular endothel-
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ium (232), which further supports the concept of endothelial cell con
tractility as a mechanism of permeability regulation.
Both

and H 2 receptors have been implicated in the regulation of

microvascular permeability (193,233).
most mammalian species, the

However, it is documented that in

receptor predominates in the regulation of

transvessel fluid exchange (189,234,235).

In specific cases, some evi

dence exists for H 2 receptor mediation in microvascular permeability al
teration (189).

For example, H 2 receptor antagonists have been shown to

suppress cerebral edema caused by irradiation (236) and the edema caused
by thermal injury in the rat hind paw (237).

In addition, H 2 receptor

stimulation may also mediate microvascular permeability changes in the
rabbit heart (238) and cat ileum (239).
Ca^+ has recently been implicated in the regulation of microvascular permeability (219,230).

It is possible that extracellular Ca

may play a role in providing a source of activator Ca

2+

2+

for endothelial

cell contraction since endothelial contractile elements appear to be
present (230).

In support of this concept, it has been observed that

histamine induced microvascular leakage is Ca + dependent (219); this
2+
leakage is attenuated in the presence of Ca^r chelators (240), and cal

cium channel blockers (219,241).

VI.

Purpose of the Study
The purpose of this project is to determine whether histamine causes

2+
an alteration (enhancement) of Ca r binding to cell membranes in the
isolated rabbit heart.
To test this possibility, La

will be used as a marker for Ca

binding sites to the plasma membranes of both cardiac myocytes and endo-
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O.
thelial cells.

In previous work I showed that verapamil inhibits La

binding to the cellular surface of both cell types in the isolated rabbit
heart.

Therefore, it is reasoned that if histamine increases cellular

contractility by enhancing Ca

binding to the cell membrane, it might

cause the reappearance of La^+ binding to the plasma membrane in the
presence of verapamil.

If La^+ binding does reappear, this I believe

would serve as visual evidence that histamine enhances Ca

binding to

the plasma membrane, thus serving as a possible mechanism of action in
O ,

the regulation of its cardiovascular effects.

If alteration of La

binding does occur due to histamine, specific histamine receptor blockers
are going to be used to elucidate which receptor type mediates the en
hancement of La^+ (Ca^+ ) binding to the cellular surface.

MATERIALS AND METHODS

I.

Heart Preparation
A total of twenty-four New Zealand albino rabbits, weighing 2.0 to

3.0 kilograms were used for this project.

The rabbits were placed in a

restrainer and injected with approximately 3.0 cc of sodium pentobarbitol
(5%; Nembutal) through the marginal ear vein.

After approximately 1.0 cc

of the anesthetic had been injected, the rabbit was removed from the
restrainer and weighed.
to prevent clotting.

Subsequently 2.0 cc of heparin was administered

Anesthetic was then added in small increments until

the animal was no longer "light", i.e., exhibiting no eye movement or
sciatic nerve reflex.

The animal was then tied down, ventral side up on

a surgical board for the operative procedure.
A midline incision was made from the xyphoid process to the neck
region.

Once the chest was opened, the lungs were deflated.

The thymus

was wiped away to expose the pericardial sac and dorsal aorta in toto.
The pericardial sac was opened and removed to expose the beating heart
and aorta.

A loose ligature was placed around the aorta to eventually

hold the aortic cannula in place.

At approximately 1 to 2 centimeters

from the heart a cut was made in the aorta, and a cannula was inserted
retrograde which was tied by the ligature.

Afterward, the heart was

removed from the animal and allowed to beat in vitro via Ringer-Tyrode
solution that was being perfused through the aortic cannula.

After it

had established its own rhythm, the heart was suspended, held in place on
a plastic frame.

Two copper wire electrodes connected to a Grass S-5

stimulator were inserted into the right and left ventricles to provide
a steady pace of one hundred twenty beats per minute.
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The heart was hooked up to a force transducer (Statham UC-3) to
measure force of contraction.

The transducer was calibrated in increments

of 5 grams up to and including 15 grams.

To record the force, a copper

wire was inserted into the apex of the hanging heart, while the bottom of
the vertical wire was hung on a metal horizontal lever, which was attached
to the bottom of the plastic "T" frame.

On the other side of the lever,

a second copper wire was inserted with the bottom through the lever, and
the top hooking on to the force transducer which was attached to the frame.
The lever was then tightened via a nut and screw so that there was equal
tension on both vertical wires, as well as maintaining the lever horizontal.
A pressure transducer (Statham P23AC) was utilized to measure coro
nary perfusion pressure.

It was calibrated at 100 mm mercury.

The pres

sure transducer was hooked up by inserting a needle through the perfusion
rubber tubing approximately 20 centimeters proximal to the aortic cannula.
The needle was connected to fine polyethylene tubing which was connected
to the pressure transducer.
Both force and pressure were recorded via a Gould 2400S recorder.
The perfusion apparatus is diagrammed in Figure 7.
Sixteen different solutions were utilized for the project (see
Appendix A):
1.

Ringer Tyrode Solution

2.

HEPES - (Ringer-Tyrode) Solution

3.

Lanthanum (LaJ’t‘) - (Ringer-Tyrode) Solution

4.

Verapamil - (Ringer-Tyrode) Solution

5.

La-3'1' - Verapamil - (Ringer-Tyrode) Solution

6.

Histamine - (Ringer-Tyrode) Solution

7.

Histamine -

O,

O ,

Verapamil (Ringer-Tyrode) Solution
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8.

Histamine - Verapamil - La^+ (Ringer-Tyrode) Solution

9.

Diphenhydramine - (Ringer-Tyrode) Solution

10.

Diphenhydramine - Histamine (Ringer-Tyrode) Solution

11.

Diphenhydramine - Histamine - Verapamil (Ringer-Tyrode)
Solution

12.

Diphenhydramine - Histamine - Verapamil - La^+ (Ringer-Tyrode)
Solution

13.

Ciraetidine - (Ringer-Tyrode) Solution

14.

Cimetidine - Histamine (Ringer-Tyrode) Solution

15.

Cimetidine - Histamine - Verapamil (Ringer-Tyrode) Solution

16.

Cimetidine - Histamine - Verapamil - La^+ (Ringer-Tyrode)
Solution

The normal Ringer-Tyrode solution was pH 7.08, while all others were
at a pH of 7.40.

Solutions #1 and 2 were control solutions.

The normal

Ringer-Tyrode solution was used initially as the heart recovered well from
O .

surgery with that solution.

To prepare the hearts for La

perfusion,

and to be consistent as a control for non-La^+ perfused hearts, HEPES
Ringer-Tyrode solution was perfused after control #1 solution to remove
HCOg , SO^

II.

9

and CO3

9—

which readily precipitate with La

.

Protocol
Six sets of experiments were performed for analysis.

Four hearts

were used for each experiment.

A.

Control Hearts

These hearts were perfused with the Normal Ringer-Tyrode Solution
(#1) and subsequently the HEPES Ringer-Tyrode Solution (#2) until stabil
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ization of force and perfusion pressure occurred.

B.

Lanthanum Treated Hearts

After stabilization was established via the Normal Ringer-Tyrode
Solution (#1) and HEPES Ringer-Tyrode Solution (#2), these hearts were
then perfused with the La^+ Ringer-Tyrode Solution (#3) for one-half hour.

C.

Lanthanum-Verapamil Treated Hearts

Once the hearts were stabilized on both the normal (#1) and HEPES
Ringer-Tyrode solution (#2), Verapamil Ringer-Tyrode solution (#4) was
O

I

perfused for one-half hour, and immediately afterwards the La

- Verapa

mil Ringer-Tyrode solution (#5) was perfused for one-half hour.

D.

Histamine Treated Hearts

Once the hearts were stabilized on both normal (#1) and HEPES (#2)
solutions, Histamine Ringer-Tyrode solution (#6 ) was perfused for three
minutes as a pre-treatment, followed by perfusion for one-half hour on
Histamine-Verapamil Ringer-Tyrode solution (#7), and subsequently perfusion
O»
for one-half hour on Histamine-Verapamil-La0'1' Ringer-Tyrode (#8 ) solution.

E.

Diphenhydramine Treated Hearts

After initial stabilization occurred, all hearts were perfused with
Diphenhydramine Ringer-Tyrode solution (#9) for six minutes as a pretreatment.

Thereafter, the perfusion protocol was similar to protocol

#4 (after stabilization), except that all solutions had diphenhydramine
present.
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F.

Cimetidine Treated Hearts

This protocol is similar to protocol #5, except that cimetidine
(solution #13-16) has been substituted for diphenhydramine (solution #912).

All solutions were driven by a Masterflex Tubing pump (Model #7567),
at a flow rate of approximately 47.0 mis per minute.

The solutions were

warmed to approximately 26.5°C by a Therraomix 1441 water temperature bath
(B. Braun Schutzart 1P21).

The pump consisted of four heads which en

abled it to pump four solutions simultaneously at a constant flow rate.
All solutions were passed via polyethylene tubing through the water
temperature bath and into designated gas traps for each perfusion line.
After leaving the gas traps, the perfusate passed through rubber tubing
into the hanging heart via the aortic cannula.

Plastic junctions were

inserted into the rubber tubing to ensure separation of perfusate lines.
As one perfusate was being utilized, the other three were able to re
cycle back through corresponding input lines.
responding input and output line.

Each pump line had a cor

Perfusate switches could be made in

stantaneously by clamping the proper input and output lines.

The over

flowing perfusate from the heart was collected in a beaker and subseO.
quently discarded.

All solutions containing La

were passed through a

Balston DFV Grade DQ filter (0.45 y millipore) to trap any La^+ precipi
tate present in the solution.
The normal Ringer-Tyrode solution was bubbled with a mixture of gas
containing 95% oxygen and 5% carbon dioxide, while solutions containing
HEPES buffer were bubbled with 100% oxygen.
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III. Electron Microscopy Preparation
A.

Fixation

Immediately following the experimental protocols described above,
the rabbit hearts were prepared for transmission electron microscopic (TEM)
analysis by initial perfusion fixation.

A "washout” solution was first

perfused via retrograde aortic perfusion for approximately fifteen minutes.

"Washout Solution" (dilute Karnovsky paraformaldehyde-glutaraldehyde fix
ative) :
paraformaldehyde

6 .6 gm/L

25% glutaraldehyde (biological grade)

2.3 ml/L

0.2N cacodylate buffer (pH 7.2-7.4)

360 ml/L

CaCl 2

0.50 gm/L

AICI 3

0.25 gm/L
360 ml/L

distilled H 20

(Add enough H20 to make 1L) and 0.1% Procaine

After the initial fixative perfusion, a stronger Karnovsky fixative
was used to complete the perfusion fixation.

The second fixative was

perfused through the heart for approximately fifteen minutes.

Karnovsky's Solution:
paraformaldehyde

10.0 gm/L

25% glutaraldehyde (biologicalgrade)
0.2N Cacodylate buffer

(pH7.2-7.4)

50 ml/L
360 ml/L

CaCl 2

0.50 gm/L

AlClg

0.50 gm/L
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distilled H 20

500 ml/L

(Add enough distilled H20 to make 1L.)

Both fixatives were prepared in a similar manner.
was allowed to steam slightly.
while stirring.

Distilled water

Afterward, the paraformaldehyde was added

1 N sodium hydroxide was added drop by drop until the

cloudiness of the paraformaldehyde disappeared.

The solution was cooled

and the undiluted glutaraldehyde, then the cacodylate buffer was added.
Finally, both aluminum chloride and calcium chloride were dissolved and
distilled water added to the designated total solution volume.

The fix

atives were then adjusted to their proper physiological pH of 7.4.

The cacodylate buffer (0.2 N) components were as follows:
cacodylic acid

3.2 g/100 ml H20

♦sucrose

0.4 gm/100 ml H20

pH to 7.4
♦Sucrose was added to correct the osmolality from 292 mOsm to approx
imately 300 mOsm.

B.

Post-fixation

After perfusion fixation, the heart was taken down and weighed on a
Mettler balance.

Heart weights ranged from 7.0 to 10.0 gms.

cut into fine pieces and placed in separate vials.
ected for analysis; the atria and ventricles.

They were

Four areas were sel

Small sections were im

mersed in Karnovsky fixative for approximately 2 hours to ensure total
fixation.

After immersion, fixation the cut pieces were washed with 0.2 N

cacodylate buffer for approximately one minute.

After washing of the

43

tissue, post-fixation was done by covering the tissue with a 50:50 solu
tion of 0.144 N cacodylate buffer and 2% osmic acid (OsO^) for 1.5 hours.
The vials were shaken to ensure thorough penetration of the OsO^.

0.144 N cacodylate buffer:
cacodylic acid

2.32 g/100 ml 1^0

*sucrose

3.0 gm/100 ml H 2 O

pH to 7.4
*Sucrose is added to adjust the osmolarity from 218 Osm to 300 Osm.

2% Osmic acid (0s0^) solution:
A— 1 gm 0s0^ in 25 ml distilled H 2 O
B— 0.58 gm Na cacodylate (1 N NaOH to pH 7.4) and equal amounts of
h 2°

C— 0.25 gm CaCl2 in 25 ml distilled H 2 O
D— dilute to 2 % with distilled H 2 O

After post-fixation, the tissue was washed in 0.144 N cacodylate
buffer for one minute.

C.

Dehydration and Embedding

The next step for TEM preparation was dehydration of the tissue.

A

graded series of ethanol transfers was used for the removal of ^ 0.
Transfers (in order) of 30%, 50%, 70% and 80% ethanol for five minutes
each was done.

Afterwards, the tissue was immersed in 95% ethanol twice

for 10 minutes each.
After the second immersion of 95% ethanol, the cut pieces were cov-
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ered with 100% ethanol twice for 20 minutes each.

Once dehydration was

completed, 10 0 % propylene oxide was added after removal of the ethanol.
This was done twice for 15 minutes each.

Afterwards, a 1:1 mixture of

propylene oxide and Epon was added to the tissue for approximately one
hour.

To complete the propylene oxide series, a 1:3 mixture of propylene

oxide to Epon was added for 4 hours after removal of the 1:1 mixture.
100% Epon-Araldite was then added for one hour after the 1:3 mixture had
been removed.

It is to be noted that all solution transfers to the tis

sue were done by micropipette.
the same manner.

All removals of solutions were done in

The tissue was never removed from the vials.

After the addition of 100% Epon for one hour, the tissue pieces were
placed in embedding block molds and embedded in 100% Epon-Araldite.

Each

block was also numbered by placing a typed number inside the embedding
medium with the tissue.

The embedding blocks were then placed in an oven

at 60°C for approximately 36 hours.

Upon removal of the blocks from the

oven, they were allowed to cool and subsequently removed from the embed
ding mold.

Epon-Araldite:
Epon Resin 812

10 ml

Araldite 506

10 ml

Dodecenyl-succinic anhydride (DDSA)

24 ml

2,4,6 Tri (dimethyl-aminomethyl) phenol

D.

30 drops = .96 ml

Sectioning

The embedded blocks were trimmed down by razor blade so that the
blocks could be sectioned for tissue samples.

After trimming, the blocks
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were thick sectioned by glass knife on a Sorvall Porter-Blum MT2-B Ultramicrotome.

The glass knives were cut on an LKB Knifemaker-Type 7801 A.

Thick sections were approximately 1 to 1.5 ym thick.

The thick sections

were then stained with toluidine blue and viewed by light microscopy to
determine the condition of the tissue.

The blocks were then thin sec

tioned on the microtome with a 2.7 mm Diatome diamond knife (MP 2840).
Thin sections were approximately 60-90 nm thick; they were collected on
200 mesh copper grids (Pelco), and subsequently examined with a JEOL JEM100S transmission electron microscope at 80 kv.

E.

Photography

Photomicrographs of unstained tissue were taken using Kodak elec
tron microscope film #4489 (3 1/4" x 4").

The negatives were developed

using a Kodak model 90B Nitrogen Intermittent Gas Burst Valve system.
Nitrogen was pumped into Kodak D-19 developer every 8 seconds for a dura
tion of 0.8 seconds.

This was done for 4 minutes.

The negatives were

washed for 10 seconds and subsequently fixed for 10 minutes using Kodak
fixer.

They were then washed in running 1^0 for 20 minutes and dipped in

Kodak Photo-Flo 200 Solution for one minute.
minutes.
larger.

They were then dried for 20

File prints were made using a Besler 45 MX photographic en
Kodak #191-9471 Ectamatic SC paper-F (8 " x 10" and 8 1/2" x 11")

was used.

The paper was developed via a Kodak 52 phototypesetting pro

cessor using Kodak Ectaflex activator and stabilizer.

The prints were

then post-fixed in Kodak fixer for 5 minutes and washed in a Pakolux 1^0
bath with a Wing-Lynch Electronic 1^0 Temperature Controller (6 8 °F) for
45 minutes.

The prints were then placed in Pakosal wetting solution for

one minute and subsequently dried using an Arkay dual-dry Profession Model
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150 dryer.

IV.

Materials
The following materials are from their respective companies:
A.

Sigma
Potassium chloride, calcium chloride, HEPES (N-2-hydroxyethylpiperazine-N^-2-ethane sulfonic acid), lanthanum chloride, mag
nesium sulfate, sucrose, procaine, cacodylic acid, heparin,
uranyl acetate, lead citrate, sodium hydroxide, diphenhydramine
hydrochloride, cimetidine

B.

Mallinckrodt
Magnesium chloride

C.

Fischer
Dodecenyl succinic anhydride, Epon Resin 812

D.

Tousimis
Araldite 506, osmium tetroxide, 50% glutaraldehyde (pure grade)

E.

MCB Reagents
Sodium chloride, glucose, sodium bicarbonate

F.

Abbott
Sodium pentobarbitol (Nembutal)
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G.

Knoll
Verapamil-HCl

RESULTS

I.

Control Tissue
Figures 8 and 9 depict representative cardiac tissue that has been

perfused with control solution.

As can be seen, all of the various or

ganelles such as mitochondria, plasraaleramal vesicles, the sarcolemmalglycocalyx complex, etc. appear intact indicating proper fixation tech
nique .

II.

Lanthanum Treated Tissue
Figures 10 and 11 exhibit representative cardiac tissue that has

been treated with 10 mM La^+ for 30 minutes.

La^+ binding is apparent on

the sarcolemmal-glycocalyx complex and cytoplasmic vesicles of cardiac
myocytes.

O.
From Table 2 it can be seen that La-" binding was present on

well over 90% of the cardiac myocytes examined.
La^+ binding also occurred on vascular endothelial membranes.

Spe

cifically, La^+ binding was present on both adluminal and abluminal sur
faces of endothelial cells.

In the analysis of 111 microvessels (Table

1) for La^+ , 103 exhibited La^+ binding.

Out of the 111 microvessels ex

amined for La^+, 104 had La^+ present on the adluminal surface (93%) and
94 (85%) had La^+ binding on the abluminal surface.
O,
In addition to surface membrane binding, La

was prevalent on endo

thelial plasmalemmal vesicles and at endothelial junctions.

III. Verapamil Treated Tissue
Figures 12 and 13 depict examples of rabbit myocardium that were
pre-treated with 10-^ M verapamil for 30 minutes, and then perfused with
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__ cr

a combination of 10 mM La 'r and 10

M verapamil for 30 minutes.

The ap

pearance of the tissue is similar to control tissue of Figures 8 and 9,
as the sarcolemmal-glycocalyx complex and cytoplasmic vesicles of cardiac
O.
myocytes appear free of La

binding.

This phenomenon occurred in all

cardiac myocytes examined.
In addition, the vascular endothelial plasma membranes (adluminal
O.
and abluminal) and plasmalemmal vesicles show no La T binding.

SpecifiO.
cally, out of 107 microvessels examined for the presence of LaJ (Table
1) only 4 microvessels (2%) were bound by La^+.

This binding occurred on

the adluminal surface only.

IV.

Histamine Treated Tissue
Figures 14 and 15 represent 1.1 x 10“^ M histamine treated myocar

dial tissue.

Specifically, histamine was used as a pre-treatment for 3

minutes before perfusing with histamine-verapamil and a combination of
histamine, verapamil and lanthanum (concentrations stated previously) for
30 minutes each.
The histamine pre-treated cardiac myocytes and vascular endothelial
cells appear visually similar to those treated with La

alone.

La

is

uniformly bound to the sarcolemmal-glycocalyx complex of a representa
tive cardiac myocyte.

While not all histamine treated cardiac myocytes

exhibited La^+ binding, Figure 14 is representative in that 90 out of 108
(83%) histamine treated cardiac cells examined showed La

binding (Table

2) . This is significant when contrasted with verapamil-treated cells,
none of which had any La

binding present.

From the data in Table 1, out of 119 histamine treated microvessels
analyzed for the presence of La

, 109 exhibited La

binding.

Binding
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was present on both adlurainal and abluminal surfaces.

However, a larger

percentage of La^+ binding (92% to 72%) was present on the adlurainal sur
face.

This finding is consistent with the analysis of La^+ treated
OI

microvessls which also had a lower percentage of (85% to 93%) La

bind-

O.
ing on the abluminal surface.

Vesicular La

binding also occurred on
O i

plasmalemraal vesicles (Figure 15).

In addition, LaJ_r binding occurred

across endothelial junctions.

V.

Diphenhydramine Treated Tissue
Figures 16-18 represent cardiac tissue that has been pre-treated for

6 minutes with 3.4 x 10~^ M diphenhydramine, an Hj blocker, before per
fusing with histamine, verapamil and lanthanum (see Materials and Meth
ods).

From the data summarized in Table 1, out of 105 microvessels ex-

O.
O.
amined for the presence of LaJ , 60 (57%) exhibited La 'r binding on the
O i

adluminal surface, and 45 (43%) had LaJi_ present on the abluminal surO ,

face.

La "r binding was also present on plasmalemmal vesicles and across

endothelial intercellular clefts.
Although the majority of the diphenhydramine treated microvasculaO .

ture had La

»

binding present, the results are significant in that the
O i

percentage of La

bound microvessels due to histamine was attenuated in

the presence of diphenhydramine.
Diphenhydramine treated cardiac myocytes were also examined (see
Table 2).

Figure 17 is representative in that at least 83% of all cardiac
O .

myocytes observed had La "r binding present on the sarcolemmal-glycocalyx
complex.

La^+ was also present on most cytoplasmic vesicles when vesi

cles were present.
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VI.

Cimetidine Treated Tissue
Figures 19 and 20 are examples of rabbit myocardium that has been

treated with 4.0 x 10-^ M cimetidine, an H 2 blocker.

Specifically, the

protocol for cimetidine treatment is similar to diphenhydramine treated
tissue (see Materials and Methods).

As can be seen from the data in Table
O .

O .

1, out of 106 microvessels examined for La01" binding, 56 (53%) had LaJr
binding present on the adluminal surface, and 35 microvessels (33%) had
La^+ binding on the abluminal surface.

As seen in diphenhydramine treated

O ,

myocardium, the number of La "r bound microvessels due to histamine was
greatly attenuated in the presence of cimetidine.

O,
La T binding was also

present on plasmalemmal vesicles and between adjacent endothelial cells
via endothelial cell junctions.
In contrast to diphenhydramine, cimetidine had a mitigating effect
O .

on the percentage of La ^ bound cardiac myocytes.

From the data in Table

2, analysis of the tissue revealed that out of 105 cardiac myocytes
O ,

examined, 57 exhibited no La

binding.

This is significant in that the
•31

percentage of cimetidine treated cardiac myocytes not bound with La
O,
(54%) represent the major effect of an H 2 blocker on La T binding in rab
bit myocardium.

La^+ binding that is present is found on the sarcolem-

mal-glycocalyx complex and on most cytoplasmic vesicles when they are
present.

VII. General Comments
The density of La
siderably.

3+

present on rabbit cardiac tissue varied con

La^+ binding, when it occurred in any experimental protocol

varied from light, scattered particles to a more dense precipitate.

In

general, La^+ binding is more uniform (i.e. of the same density) on the
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sarcolemmal-glycocalyx complex of cardiac myocytes.

Vascular endothelial

plasma membranes exhibit non-uniform La^+ binding to a greater degree.
O.
It appears that La

binding on endothelial cell surfaces is more of the
O ,

vesicular nature, i.e. La

seems to concentrate on areas of the cell

membrane that may invaginate to form plasmalemmal vesicles.
A general finding of this study is that all phenomena observed (i.e.
La^+ binding, inhibition of binding by verapamil, reversal of the verapa
mil effect by histamine as well as alteration of histamine's effect via
and H 2 blockers) occurred in both atria and ventricles, suggesting a gen
eralized effect of histmine on all plasma membranes in the rabbit heart.

DISCUSSION

I.

Effect of Lanthanum
O ,

Several lines of work support our use of La

O .

as a marker for Ca

O ,

binding sites.

La

, a member of the lanthanide series of earth metals

(25), is opaque under transmission electron microscopy and has long been
used as a stain for biological membranes (109,112).
O .

teraction with Ca

Relative to its in-

O ,

binding sites, La

has been shown to inhibit super-

O i

ficial binding and uptake of Ca

in a variety of tissues, including in

testinal, uterine and vascular smooth muscle cells, cardiac myocytes and
vascular endothelial cell membranes (117,119,121,127).

Of particular

relevance to the present study is the evidence that 90 to 100% of the Ca^+
bound to the sarcolemmal-glycocalyx complex of cardiac muscle cells may
be displaced by La^+ (117).
La^+ binding occurred extensively (over 90%) in all tissue examO ,

ined.

Specifically, when 10 mM La

was used, binding occurred on the

sarcolemmal-glycocalyx complex and cytoplasmic vesicles of cardiac myocytes.
O .

La°"f" binding was also present on cell membranes (adluminal and ablurainal)
O ,

and plasmalemmal vesicles of vascular endothelia.

The binding of La

to

plasma membranes of cardiac myocytes is consistent with the findings of
O

I

Langer (117) who observed that La ^ binds to the sarcolemmal-glycocalyx
O

complex.

In vascular endothelium, it was found that some La

to endothelial clefts.

i

was bound

This is consistent with the findings of Pederson

(120) who demonstrated the permeability properties of endothelium by
O ,

using La

as an intercellular marker.

In addition, Weihe (127) found

that both luminal surfaces of vascular endothelium have a great affinity
for lanthanum.

Our findings substantiate this observation.
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It was also
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seen that La^+ binds to cytoplasmic vesicles (127); our results are con
sistent with this finding.

II.

Effect of Verapamil
From the results obtained, it is apparent that the calcium channel
r

O .

blocker, verapamil, (10 J M) inhibits LaJ',‘ from binding sites on plasma
membranes and cytoplasmic vesicles of both cardiac myocytes and vascular
endothelium.

If, as prior investigators suggest (108,127), La^+ is a

marker for calcium binding sites, then it can be concluded that these re
sults serve as visual evidence that calcium channel blockers inhibit cal
cium binding at the cellular membrane level.
The plasma membranes of cardiac myocytes are thought to contain two
types of calcium channels; receptor-operated channels, and potential de
pendent channels (49).
and the ROC’s (49).

Verapamil is postulated to bind at both the PDC’s

Since La^+ binding was completely inhibited by verO ,

apamil, it is possible that La

binding is associated with one or both

of these calcium channels.
O ,

The fact that verapamil inhibits La

binding from cytoplasmic ves

icles suggests a mode of intracellular penetration of verapamil.

The

lipophilic nature of verapamil (150,164) supports this theory of penetra
tion.

The work of other experimenters has shown possible intracellular

accumulation of calcium channel blockers.

For example, it has been ob

served that channel blockers may interact with mitochondria (167) and
the regulatory protein, calmodulin (168).
Verapamil also inhibited La^+ binding to the cell membranes (adlumiO .

nal and abluminal) of vascular endothelia.

Verapamil, like La

, may

penetrate vascular endothelium via intercellular clefts or plasmalemmal

55

vesicle formation.

The implications of this effect are two-fold.

First,

verapamil may interfere with calcium transport itself across the vascular
endothelium.

Second, verapamil may interfere with vascular endothelial

integrity to such a degree as to alter exchange of other substances across
the endothelia.

This latter possibility is suggested by work which has

shown that zero calcium solutions may enhance capillary membrane perme
ability (242,243).

III. Effect of Histamine
A.

General

When histamine (1.1 x 10"^ M) was used, it was observed that inhibi
tion of La^+ binding seen in the presence of verapamil was reversed.

This

effect was seen on the plasma membranes and cytoplasmic vesicles of both
cardiac myocytes and vascular endothelium as at least 80% of each tissue
type had La^+ binding present.

Therefore, it can be inferred that his

tamine enhances Ca^+ binding to plasma membranes of both cardiac muscle
and endothelial cells.

B.

Myocardial effect

In regard to cardiac muscle, it has been documented that Ca

2+

bind

ing to the sarcolemmal-glycocalyx complex is essential in the regulation
of excitation-contraction coupling (26,27).

Further, it has been suggested

2+

that Ca ^ is released from the sarcolemmal-glycocalyx complex to activate
contraction (26).

Depending on species, this surface bound Ca

may, on

entering the cell, either directly initiate contraction or induce release
of Ca^+ from intracellular stores (primarily SR) which in turn causes
contraction (15,32,244,245).

The fact that histamine has a positive ino
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tropic and chronotropic effect in the heart (190,192,246) coupled with
the evidence that these positive effects are associated with enhanced Ca
influx (212,213,247) suggests that the membrane bound stores of Ca
be affected by histamine and are probably enhanced.

oi

might

This possibility was

supported in the present study by the observation that histamine caused
the re-appearance of La^+ binding to the myocardial cellular surface in
the presence of verapamil.
hances Ca

Therefore, it may inferred that histamine en-

binding to the sarcolemmal-glycocalyx complex of cardiac myo

cytes, thereby accounting for its positive inotropic and chronotropic
activity.

C.

Effect on Microvascular Endothelium

Anatomical evidence suggests that a possible mechanism of action of
histamine to increase microvascular permeability involves an endothelial
contractile response.

If this contractile response does occur, it is

possible that increased Ca

binding to the cell membrane is a necessary

prerequisite to such an effect, as seen in cardiac and smooth muscle.
o

.

Since histamine enhanced La

binding to vascular endothelial mem

branes in the presence of verapamil it can be inferred that histamine increases Ca

binding to plasma membranes of endothelial cells.

By en-

hancing Ca T binding to vascular endothelium, it is possible that hista
mine could evoke an endothelial contractile response as proposed by Majno
et al., (225) and Fox et al., (218).

If indeed endothelial cells possess

contractile machinery similar to muscle (230) it is conceivable that a
contractile response could be induced by increased Ca

binding to the

endothelial membrane, via a similar mechanism as postulated in smooth and
cardiac muscle.

The endothelial contractile response caused by increased
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Ca

2+

binding could then cause the formation of endothelial gaps to appear

which would enhance vascular permeability.

Further evidence for hista-

mine's mechanism of action employing a Ca^"1" mechanism in the regulation
of microvascular permeability is seen in the work of Mayhan and Joyner
(219), who observed that in the presence of a high Ca

buffer, hista

mine's effect on microvascular permeability was enhanced, and this response
was reduced in the presence of buffer containing 10-^ M verapamil.
The actual mechanism of action by which histamine causes an enhance
ment of La^+ binding to plasma membranes of rabbit myocardium needs to be
determined.

For example, it is possible that histamine may affect the

affinity of Ca^+ binding sites for Ca^+, or that new Ca^+ binding sites
may appear on the cell surface upon exposure to histamine.

Since ques

tions of this type are difficult to answer anatomically, a pharmacologi
cal (receptor binding) approach may be necessary to further elucidate the
mechanism of action of histamine's effect on Caz‘t’ binding.

IV.

Effect of Diphenhydramine
Diphenhydramine, an H^-receptor blocker, was used to determine if
O

I

histamine's effect on La° , i.e. Ca
rabbit heart is

O

.

, binding to cell membranes of the

receptor mediated.

As can be seen from Table 1, 3.4 x 10~^ M diphenhydramine appeared
to reduce La^+ binding to the cell membranes of vascular endothelial
cells; specifically, 57% of all diphenhydramine-treated microvessels ex
amined exhibited La^+ binding as compared to 92% of those treated with
histamine alone.
From these results, it would appear that diphenhydramine has a great
effect on the microvasculature indicating that histamine's effect on
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O ,

La

O .

, i.e. Ca

, binding to the endothelial cell membrane may be partially

Hj receptor mediated.
In support of this finding, it has been documented that the regula
tion of microvascular permeability is partially
(193).

receptor mediated

It has also been observed that histamine may increase microvascu

lar permeability through the formation of endothelial gaps (225).

These

endothelial gaps are believed to be formed as the result of an endothel
ial contractile response (225,230).

If extracellular Ca^+ is involved in

this contractile response as is seen in cardiac and smooth muscle, then
O ,

histamine's effect on permeability might employ a CaZi" mechanism by spe
cifically, enhancing Ca^+ binding at the cellular membrane level.

Through

the use of La^+ as a Ca^+ marker we have demonstrated this finding.
O .

From the results obtained with diphenhydramine, an increase in Ca"1"
binding to vascular endothelial membranes by histamine may be partially
H^-receptor mediated.

Therefore, if histamine's regulation of microvas

cular permeability involves an endothelial cell contractile response via
O i

Ca T binding to the cell membrane, this response may be

receptor medi

ated.
In contrast to results obtained with vascular endothelia it would
o.
appear that alteration of Ca

binding to the sarcolemmal-glycocalyx com

plex of cardiac muscle via H^-receptor mediation is minimal as over 80%
O .

of diphenhydramine-treated myocytes (Table 2) exhibited LaJ"t" binding in
dicating that Hj-receptor blockade has relatively no effect on the hista
mine response.
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V.

Effect of Cimetidine
Cimetidine, an I^-receptor blocker, was used to determine if hisO .

O .

famine's effect on La0 , i.e. Caz , binding to plasma membranes in rabbit
myocardium is H 2 receptor mediated.
Specifically, when 4.0 x 10”^ M cimetidine was used, histamine's ef
fect on La^+ binding to the plasma membranes of both cardiac myocytes and
vascular endothelial cells was attenuated.

From Table 1, 53% of all cim-

etidine-treated microvessel membranes (i.e. adluminal, abluminal and
plasmalemmal vesicles) analyzed showed LaJ+ binding as compared to 92%
of those treated with histamine alone.

As regards cardiac myocytes, from

Table 2 it can be seen that 46% of the cimetidine-treated cells examined
had La^+ present on the sarcolemmal-glycocalyx complex or cytoplasmic
vesicles as compared to 83% of cells treated with histamine alone.
From these results, it would appear that both cardiac and vascular
endothelial cells possess a significant number of H 2 receptors and that
O .

O

histamine's effect on La0'*' i.e. Ca

1

binding to these membranes is par

tially {^-receptor mediated.
In support of this hypothesis, it has been documented that hista
mine's effect on microvascular permeability is at least partially {^-re
ceptor mediated (193,238).
ceptors (231).

In addition, endothelial cells possess H 2 re

It has also been observed that both inotropic and chrono

tropic effects of histamine in the isolated rabbit heart are I^-receptor
mediated (190,192).

VI.

Summary
It is evident from this study that histamine reversed the inhibition

of La^+ binding by verapamil to the plasma membranes of both myocardial
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and vascular endothelial cells.

By enhancing La^+ binding to the cell

membrane, it can be inferred that some of histamine's cardiovascular efO .

fects involve a Ca 'r mechanism, specifically by increasing Ca

O i

binding

at the cellular surface.
Through the use of specific histamine receptor blockers, it appears
that histamine's effect on Ca^+ binding to the endothelial membrane is Hj
and H 2 receptor mediated, while this same effect on myocardial cells only
involves H 2 receptor mediation.

APPENDIX A - PHYSIOLOGICAL SOLUTION COMPOSITION
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Ringer-Tyrode Solution:
NaCl

8.000 gra/L

(137.00 mM)

KC1

0.200 gm/L

(2.68 mM)

CaCl2*2H20

0.268 gm/L

(1.82 mM)

MgS04«7H20

0.308 gm/L

(1.25 mM)

glucose

1.000 gm/L

(5.55 mM)

NaHC03

1.000 gm/L

(11.90 mM)

HEPES - (Ringer-Tyrode) Solution:
NaCl

8.590 gm/L

(147.00 mM)

KC1

0.200 gm/L

(2.68 mM)

CaCl2*2H20

0.268 gm/L

(1.82 mM)

MgCl2*6H20

0.308 gra/L

(1.51 mM)

glucose

1.000 gm/L

(5.55 mM)

HEPES*

0.7149 gm/L

(3.00 mM)

O i

Lanthanum (La'3'’") - (Ringer-Tyrode) Solution:
NaCl

7.420 gm/L

(127.00 mM)

KC1

0.200 gm/L

(2.68 mM)

CaCl2*2H20

0.268 gm/L

(1.82 mM)

MgCl2-6H20

0.308 gm/L

(1.51 mM)

glucose

1.000 gm/L

(5.55 mM)

HEPES

0.7149 gm/L

(3.00 mM)

LaCl3*7H20

3.702 gm/L

(10.00 mM)

Verapamil - (Ringer-Tyrode) Solution:
NaCl

8.590 gm/L

(147.00 mM)
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KC1

0.200 gm/L

(2.68 mM)

CaCl2*2H20

0.268 gm/L

(1.82 mM)

MgCl2*6H20

0.308 gm/L

(1.51 mM)

glucose

1.000 gm/L

(5.55 mM)

HEPES

0.7149 gm/L

(3.00 mM)

verapamil*HCl

0.005 gm/L

(10“5 M)

*N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid

5.

6.

La^+ - Verapamil (Ringer-Tyrode) Solution:
NaCl

7.420 gm/L

(127.00 mM)

KC1

0.200 gra/L

(2.68 mM)

CaCl2*2H20

0.268 gm/L

(1.82 mM)

MgCl2*6H20

0.308 gm/L

(1.51 mM)

glucose

1.000 gm/L

(5.55 mM)

HEPES

0.7149 gm/L

(3.00 mM)

LaCl3*7H20

3.702 gm/L

(10.00 mM)

verapamil*HCl

0.005 gm/L

(10“5 M)

Histamine (Ringer-Tyrode) Solution:
NaCl

8.000 gm/L

(137.00 mM)

KC1

0.200 gm/L

(2.68 mM)

CaCl2*2H20

0.268 gm/L

(1.82 mM)

glucose

1.000 gra/L

(5.55 mM)

HEPES

0.7149 gm/L

(3.00 mM)

MgCl2*6H20

0.308 gm/L

(1.51 mM)

histamine* 2HC1

0.020 gm/L

(l.lxlO-4 M)
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7.

Histamine - Verapamil (Ringer-Tyrode) Solution:
NaCl

8.000 gm/L

(137.00 mM)

KC1

0.200 gm/L

(2.68 mM)

CaCl2-2H20

0.268 gm/L

(1.82 mM)

glucose

1.000 gm/L

(5.55 mM)

HEPES

0.7149 gm/L

(3.00 mM)

MgCl2«6H20

0.308 gm/L

(1.51 mM)

histamine*2HC1

0.020 gm/L

(l.lxlO-4 M)

verapamil*HCl

0.005 gm/L

(10-5 M)

Histamine - Verapamil - La^+ (Ringer-Tyrode) Solution:

9.

NaCl

7.420 gm/L

(127.00 mM)

KC1

0.200 gm/L

(2.68 mM)

CaCl2-2H20

0.268 gm/L

(1.82 mM)

glucose

1.000 gm/L

(5.55 mM)

HEPES

0.7149 gm/L

(3.00 mM)

MgCl2*6H20

0.308 gm/L

(1.51 mM)

histamine*2HC1

0.020 gm/L

(l.lxlO-4 M)

verapamil*HCl

0.005 gm/L

(10-5 M)

LaCl3*7H20

3.702 gm/L

(10.00 mM)

Diphenhydramine - (Ringer-Tyrode) Solution:
- similar to solution #2, with the addition of diphenhydramine (0.1
mg/L; 3.4 x 10“7 M).

10.

Diphenhydramine - Histamine (Ringer-Tyrode) Solution:
- similar to solution #6, with the addition of diphenhydramine (0.1
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mg/L; 3.4 x 10 ^ M).

11.

Diphenhydramine - Histamine - Verapamil (Ringer-Tyrode) Solution:
- similar to solution #7, with the addition of diphenhydramine (0.1
mg/L; 3.4 x 10-^ M).

O i

12.

Diphenhydramine - Histamine - Verapamil- La~H" (Ringer-Tyrode) Solution:
- similar to solution #8, with the addition of diphenhydramine (0.1
mg/L; 3.4 x 10“ ^ M).

13-16.

These solutions are similar to solutions #9-12, except that ci-

metidine (10 mg/L; 4.0 x 10“
mine.

M) is substituted for diphenhydra
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TABLE 1
Transmission Electron Microscopic (TEM) Analysis of
O .

the Microvasculature for Lanthanum (La "O Binding

Number of Vessels

Treatment

Total
Examined

With La3+
Binding

Surfaces Bound
Adlurainal (%)
Abluminal (%)

103 (93)

94 (85)

4 (2)

0 (0)

111

103

La3+-Ver

107

4

His-La3+-Verc

119

109

109 (92)

86 (72)

Di-His-La3+-Verd

105

60

60 (57)

45 (43)

C im-Hi s-La3+-Vere

106

56

56 (53)

35 (33)

La3+

®
°
^
d

10 mM lanthanum
10 mM lanthanum; lO-'5 M verapamil
1.1 x
M histamine; 10 mM lanthanum; lO-"5 M verapamil
3.4 x 10_/ M diphenhydramine; 1.1 x 10-Zt M histamine; 10 mM lanthanum;
10“ 3 M verapamil
e 4.0 x 10“3 M cimetidine; 1.1 x 10“ M histamine; 10 mM lanthanum; 10“ 3
M verapamil
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TABLE 2
TEM Analysis of Rabbit Myocardium
O ,

for La

Binding

Number of Cardiac Myocytes

Treatment

Total
Examined

With La3+
Binding

Percentage Bound

La3+

100

92

92

La3*-Ver

105

0

0

His-La3+-Verc

108

90

83

Di-His-La3+-Verd

102

85

83

Cim-Hi s-La3+-Vere

105

48

46

l 10 mM La3+
° 10 mM La3* ; 10" 3 M verapamil
^ 1.1 x 10“^ M histamine; 10 mM La3*; 10-3 M verapamil
3.4 x 10~ M diphenhydramine; 1.1 x 10“^ M histamine; 10 mM La3*,
10" 3 M verapamil
e 4.0 x 10-3 M ciraetidine; 1.1 x 10"^ M histamine; 10 mM La3*; 10“ 3 M
verapamil
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